Adoptive Cell Therapy Across Cancer Diagnoses

NCT ID: NCT03296137

Last Updated: 2024-10-26

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 25 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-10-13
• Study Completion Date: 2020-07-01

Brief Summary

This study will perform tumor-infiltrating lymphocyte (TIL)-based adoptive T-cell therapy in combination with checkpoint inhibition on cancer patients across all cancer diagnoses.

Detailed Description

Adoptive cell therapy (ACT) is a personalized form of immunotherapy, where lymphocytes isolated from the patient's own tumor tissue are expanded 1000-fold ex-vivo and then infused back into the patient. The lymphocytes are then able to recognize and attack remaining cancer cells. This approach has shown remarkable clinical results in several trials conducted worldwide for patients with advanced melanoma - some with durable remissions. Promising clinical results were obtained in smaller trials where patients with disparate solid tumors were treated with tumor-infiltrating lymphocytes (TILs). At Center for Cancer Immune Therapy (CCIT) at Herlev Hospital, there are currently clinical trials undergoing in ovarian and renal cancer, and internationally ACT is being tested in an increasing number of cancer diagnoses, some trials are even recruiting patients across cancer types. Studies have shown that a high intratumoral infiltration with TILs in is correlated to the general clinical outcome of the disease in virtually all solid tumors, and thus clinical trials with TIL-based ACT to different cancer diagnoses have been undertaken.

To support the TIL-mediated tumor elimination, in classical ACT protocols patients go through a highly specialized treatment regime before and after TIL infusion. This regime includes lymphodepletion with 7 days non-myeloablative chemotherapy, to provide an immunological window of opportunity for the infused TILs, and concomitant immune stimulation with interleukin-2 (IL-2). Checkpoint inhibition to support the anti-tumor activity of TILs is currently under extensive investigation in several other trials worldwide. Thus, lymphodepletion and IL-2 stimulation are well-established as supportive therapy and already an integrated part of current ACT protocols and while checkpoint inhibition is a new addition at CCIT; internationally other centers have ongoing comparable trials.

Drug-based immunotherapy in the form of checkpoint inhibitors (anti-PD-1 and anti-CTLA-4) has yielded impressive clinical results across tumor histologies. Recent results indicate that the effect of immunotherapy relies not so much on the cancer diagnoses but rather on the genomic and immunologic features of the individual patient's cancer disease. Both ACT and checkpoint inhibition work by tipping the immunological balance in favor of activation and away from suppression or avoidance by the cancer cells. Scientific evidence now show that administering anti-CTLA-4 and PD-1 could provide a benefit in the ACT setting, and several ongoing clinical trials are testing combinations of ACT and checkpoint inhibition. To synergistically maximize the immunological potential, we wish to combine ACT with an anti-CTLA-4 antibody (Ipilimumab) prior to tumor resection and an anti-PD-1 antibody (Nivolumab) in combination with TIL infusion.

Patients will be treated with one dose of Ipilimumab 14 days before undergoing surgery to harvest tumor material for TIL production. Patients is admitted on day -8 in order to undergo lymphodepleting chemotherapy with cyclophosphamide and fludara starting day -7. On day -2 patients will start treatment with Nivolumab every 2 weeks for a total of 4 doses to increase the activity of the infused TIL product.

Available evidence indicates that ACT is a safe and feasible treatment option in an increasing number of solid tumors, and that it should be tested in all cancer patients regardless of their cancer diagnosis.

Conditions

Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Tumor-infiltrating Lymphocyte (TIL) Therapy with checkpoint inhibitors

Group Type: EXPERIMENTAL

Autologous tumor-infiltrating lymphocytes

Intervention Type: BIOLOGICAL

Tumor-infiltrating lymphocytes grown ex-vivo from resected from cancer tissue and reapplied to the patient via an intravenous infusion.

Ipilimumab

Intervention Type: DRUG

One treatment with ipilimumab (3 mg/kg) prior to tumor resection.

Nivolumab

Intervention Type: DRUG

4 doses of nivolumab. Starting 2 days prior to TIL infusion and every 2 weeks hereafter.

proleukin

Intervention Type: DRUG

2 MIE s.c. injection, after TIL infusion and continuing for 2 weeks

Cyclophosphamide

Intervention Type: DRUG

2 doses (60 mg/kg) prior to TIL infusion

Fludara

Intervention Type: DRUG

5 doses (25 mg/m2) prior to TIL infusion

Interventions

Autologous tumor-infiltrating lymphocytes

Tumor-infiltrating lymphocytes grown ex-vivo from resected from cancer tissue and reapplied to the patient via an intravenous infusion.

Intervention Type: BIOLOGICAL

Ipilimumab

One treatment with ipilimumab (3 mg/kg) prior to tumor resection.

Intervention Type: DRUG

Nivolumab

4 doses of nivolumab. Starting 2 days prior to TIL infusion and every 2 weeks hereafter.

Intervention Type: DRUG

proleukin

2 MIE s.c. injection, after TIL infusion and continuing for 2 weeks

Intervention Type: DRUG

Cyclophosphamide

2 doses (60 mg/kg) prior to TIL infusion

Intervention Type: DRUG

Fludara

5 doses (25 mg/m2) prior to TIL infusion

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Histologically verified metastatic or locally advanced cancer diagnosis
• At least one lesion (>1 cm3) available for surgical resection
• Not candidate for standard treatment options
• Age of 18-70 years
• Performance status of 1 or 0.
• Life expectancy > 6 months
• One or more measurable parameter according to RECIST 1.1.
• No significant toxicity from previous cancer treatments (CTC≤1). Except alopecia (CTC≤2) or neuropathy (CTC≤2)
• Sufficient organ function, including:
• Absolute neutrophil count (ANC) ≥ 1.500 /µl
• Leucocyte count ≥ normal limit
• Platelets ≥ 100.000 /µl and <700.000 /µl
• Hemoglobin ≥ 6,0 mmol/l (regardless of prior transfusion)
• S-creatinine < 140
• S-bilirubin ≤ 1,5 times upper normal limit
• ASAT/ALAT ≤ 2,5 times upper normal limit
• Alkaline phosphatase ≤ 5 times upper normal limit
• Lactate dehydrogenase (LDH) ≤ 5 times upper normal limit
• Sufficient coagulation: PP-time>40 and INR<1,5
• Women in the fertile age must use effective contraception. This applies from inclusion and until 6 months after treatment. Birth control pills, spiral, depot injection with gestagen, subdermal implantation, hormonal vaginal ring and transdermal depot patch are all considered safe contraceptives.
• Signed statement of consent after receiving oral and written study information
• Willingness to participate in the planned treatment and follow-up and capable of handling toxicities.

Exclusion Criteria

• A history of prior malignancies. Patients treated for another malignancy can only participate if they are without signs of disease for a minimum of 3 years after last treatment.
• Primary brain tumor or verified brain metastases
• Known hypersensitivity to one of the active drugs or excipients.
• Significant medical conditions, including but not limited to severe asthma/COLD, significant cardiac disease, poorly regulated insulin dependent diabetes mellitus.
• Creatinine clearance below 70 ml/min .
• Acute or chronic infections with HIV, hepatitis, syphilis etc.
• Severe allergies or previous anaphylactic reactions.
• Active autoimmune disease, such as autoimmune neutropenia/thrombocytopenia or hemolytic anemia, systemic lupus erythematosus, Sjögren's syndrome, sclerodermia, myasthenia gravis, goodpastures disease, addison's disease, hashimoto's thyroiditis, graves' disease etc.
• Pregnant women and women who are breastfeeding.
• Simultaneous treatment with systemic immunosuppressive drugs (including prednisolone methotrexate etc.)
• Simultaneous treatment with other experimental drugs.
• Simultaneous treatment with other systemic anti-cancer treatments.
• Patients with active or uncontrollable hypercalcemia.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Inge Marie Svane

OTHER

Sponsor Role: lead

Responsible Party

Inge Marie Svane

M.D. Professor

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Anders H Kverneland, MD

Role: PRINCIPAL_INVESTIGATOR

Center for Cancer Immune Therapy, Herlev Hospital

Inge Marie Svane, MD, Prof.

Role: STUDY_DIRECTOR

Center for Cancer Immune Therapy, Herlev Hospital

Locations

Center for Cancer immune Therapy (CCIT), Dept. of Hematology and dept. of Oncology

Copenhagen, , Denmark

Countries

Denmark

References

Kverneland AH, Chamberlain CA, Borch TH, Nielsen M, Mork SK, Kjeldsen JW, Lorentzen CL, Jorgensen LP, Riis LB, Yde CW, Met O, Donia M, Svane IM. Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types. J Immunother Cancer. 2021 Oct;9(10):e003499. doi: 10.1136/jitc-2021-003499.

Reference Type: DERIVED

PMID: 34607899 (View on PubMed)

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

AA1720

Identifier Type: -

Identifier Source: org_study_id